Regenxbio inc. (RGNX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities
Net loss

-40,038

-26,464

-34,584

-1,457

-32,228

4,306

-19,202

10,594

104,239

-15,997

-20,706

-14,473

-21,993

-19,608

-18,154

-14,437

-10,768

-5,176

-7,334

-6,290

-4,011

Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense

8,017

6,875

7,162

7,099

5,718

4,886

4,483

3,981

3,291

2,796

2,735

2,483

2,591

2,000

1,829

1,656

1,546

862

1,348

635

76

Net amortization of premiums and accretion of discounts on marketable debt securities

-39

111

297

420

368

134

-171

-340

-378

-405

-465

-476

-469

-502

-515

-516

-471

-

-

-

-

Depreciation and amortization

1,994

1,971

1,866

1,749

1,614

1,329

941

896

834

737

706

703

554

280

160

56

48

37

28

15

0

Net realized gains on sales and maturities of marketable securities

7,085

-

-

-

-

-

-

-

-

0

-1

0

480

-

-

-

-

-

-

-

-

Imputed interest income from licensing

848

860

716

762

613

584

109

6,898

1,355

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized losses on marketable equity securities

12,196

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized foreign currency transaction gains

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

128

-121

Imputed interest on related party promissory notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

13

Other non-cash adjustments

-25

89

85

-115

-327

-2

1

-3

-10

-34

1

1

-41

-

-

-

13

-

-

-

-

Changes in operating assets and liabilities
Accounts receivable

5,744

-2,077

9,280

2,010

-591

23,789

1,893

-60,293

51,414

-411

832

-179

-803

386

-106

-1,240

-113

1,542

-92

-854

-331

Prepaid expenses

947

-445

884

-256

790

-574

2,618

-977

-667

2,109

793

589

68

-396

691

291

169

-380

230

1,118

24

Other current assets

2,833

1,785

133

-1,714

295

-1,003

2,487

139

446

22

138

330

-88

-990

563

137

449

-

-

-

-

Operating lease right-of-use assets

-703

-719

-556

-583

-573

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-1,705

544

800

1,376

-26

665

136

631

21

26

23

96

-10

68

-27

43

55

40

88

29

11

Accounts payable

3,063

-3,811

3,565

1,458

316

-374

496

-817

477

1,479

-1,581

255

2,468

-3,409

2,665

1,112

-182

273

-268

166

419

Accrued expenses and other current liabilities

-3,813

4,892

2,947

1,975

-2,932

4,144

872

2,076

490

-1,552

3,480

1,889

-1,920

-718

1,609

1,772

1,210

1,463

-309

451

616

Operating lease liabilities

-851

-423

-661

-579

-592

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Advance payments

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-35

-92

-

-

-

-

Other related party payables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-349

-1,536

-2,671

795

Deferred rent

-

-

-

-

-

9

-60

-8

27

32

-29

-45

-44

-25

701

148

453

-

-

-

-

Other liabilities

-1,156

-16

-25

162

-644

1,814

-29

-1,056

957

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-35,573

-25,506

-29,153

-23,749

-29,297

-4,140

-19,557

70,211

58,134

-13,826

-17,136

-9,549

-17,481

-20,423

-11,818

-8,430

-7,887

-4,443

-8,395

-8,002

-1,675

Cash flows from investing activities
Purchases of marketable debt securities

30,692

62,810

21,806

26,870

79,249

125,932

180,816

84,814

54,267

22,041

0

41,405

5,188

12,810

1

11,832

20,429

-

-

-

-

Maturities of marketable debt securities

60,907

71,975

76,757

54,097

87,165

63,639

47,465

49,120

19,525

22,999

19,215

17,510

10,500

34,455

12,000

16,025

10,106

-

-

-

-

Sales of marketable equity securities

7,124

-

-

-

-

-

-

-

-

0

0

0

780

-

-

-

-

-

-

-

-

Purchases of property and equipment

4,630

1,031

2,679

5,555

2,455

4,889

3,372

2,673

2,344

2,101

450

1,680

2,929

4,435

2,223

1,075

416

128

79

209

106

Net cash provided by investing activities

32,709

14,154

52,272

21,672

5,461

-67,182

-136,723

-38,367

-37,086

-1,143

18,765

-25,575

3,163

17,435

9,799

2,893

-10,739

-144,341

-19,144

-209

-106

Proceeds from exercise of stock options

2,154

1,600

400

1,338

3,762

5,449

2,052

3,175

3,824

1,748

423

168

161

5

44

109

21

7

8

85

7

Proceeds from issuance of common stock under employee stock purchase plan

607

0

949

0

365

-3

508

0

342

0

409

0

147

-

-

-

-

-

-

-

-

Proceeds from public offerings of common stock, net of underwriting discounts and commissions

-

-

-

-

-

-

-

-

-

-

0

10,695

71,299

-

-

-

-

-

-

-

-

Issuance costs for public offerings of common stock

-

-

-

-

-

-

-

-

-

0

226

135

84

-

-

-

-

-

-

-

-

Net cash provided by financing activities

2,761

1,549

1,333

1,367

4,127

5,288

191,814

3,175

4,166

1,741

606

10,728

71,523

-55

44

109

21

-2,424

147,648

68,058

26,028

Net decrease in cash and cash equivalents and restricted cash

-103

-9,803

24,452

-710

-19,709

-66,034

35,534

35,019

25,214

-13,228

2,235

-24,396

57,205

-3,043

-1,975

-5,428

-18,605

-151,208

120,109

59,847

24,247

Supplemental cash flow information
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

7

Supplemental disclosures of non-cash investing and financing activities
Additions to property and equipment through accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-635

877

517

422

62

22

-53

65

Issuance costs for public offerings of common stock in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-135

328

-

-

-

-

-

-

-

-

Conversion of related party promissory notes into Series C convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,389